

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-479-E

Serial No.

10/766,403

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Belardinelli

Filing Date:

1/27/04

Group:

3737

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Classes	Subclass	Filing Date if Appropriate
	4,956,345	9/11/90	Miyasaka et al			
	4,968,697	11/6/90	Hutchison			
	5,070,877	12/10/91	Mohiuddin et al			
	5,189,027	2/23/93	Miyashita et al.			
	5,270,304	12/14/93	Kogi et al			
	5,459,254	10/17/95	Yamaguchi et al.			
	5,593,975	1/14/97	Cristalli			
	5,705,491	1/6/98	Yamada			
	5,770,716	6/23/98	Khan et al.			
	5,939,543	8/17/99	Morozumi et al.			
	6,026,317	2/10/00	Verani			
	6,214,807	4/10/01	Zablocki et al.			
	6,403,567	6/11/02	Zablocki			
	US2004/0127533	7/1/04	Hart et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		02-479-E	10/766,403
		Applicant: Belardinelli	
(Use several sheets if necessary)	Filing Date:		Group:
	1/27/04		3737

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		WO 93/25677	12/13/93	PCT				
		WO 00/78779	12/28/00	PCT				
		WO 00/78778	12/28/00	PCT				
		WO 01/62979	8/30/01	PCT				
		WO 04/011010	2/5/04	PCT				
		EP 0354 638	2/14/90	EP				
		965,411	4/1/75	CA				
		Hei 5[1993]-9197	1/19/93	JP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

		Iskandrian, A, "Adenosine Myocardial Perfusion Imaging", <i>The Journal of Nuclear Medicine</i> , vol. 35, pp. 734-736 (1994).
		Gao, et al., "Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists", <i>Journal of Pharmacology and Experimental Therapeutics</i> , vol. 298, pp. 209-218 (2001).
		Marumoto, et al., "Synthesis and Coronary Vasodilating Activity of 2-Substituted Adenosines", <i>Chem. Pharm. Bull.</i> 23(4): 759-774 (1975).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-479-E	Serial No. 10/766,403
	Applicant: Belardinelli			
	Filing Date: 1/27/04	Group: 3737		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	Marumoto, et al., "Synthesis and Enzymatic Activity of Adenosine 3',5'-Cyclic Phosphate Analogs", <i>Chem.. Pharm. Bull.</i> 27(4) 990-1003 (1979).
	Persson, et al., "Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives", <i>Bioorganic & Medicinal Chemistry</i> , 3:1377-1382 (1995).
	Mager, et al., "Molecular simulation applied to 2-(N'alkylidenehydrazino)- and 2-(N'-aralkylidenehydrazino) adenosine A ₂ Agonists", <i>Eur J. Med. Chem.</i> , 30:15-25 (1995).
	Cristalli et al., "2-Alkynyl Derivatives of Adenosine 5'-N'ethyluronamide: Selective A ₂ Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation", <i>J. Med. Chem.</i> , 37:1720-1726 (1994).
	Matsuda, et al., "Nucleosides and Nucleotides. 103. 2-Alkynyladenosines: A Novel Class of Selective Adenosine A ₂ Receptor Agonists with Potent Antihypertensive Effects", <i>J. Med. Chem.</i> 35:241-252 (1992).
	Xu, et al. "Coronary Vasodilation by a Short Acting, Low Affinity A _{2A} Adenosine Receptor Agonist in Anesthetized Closed Chest Dogs: A Second Generation of Coronary Artery Pharmacologic Stressor", <i>Circulation</i> , vol. 102, no. 18, pp. 3912 (2000).

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.